Evidence map›Paper›PMID 23842135›Full record

ArticleAIDS (London, England)2013

Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993-2008: a retrospective cohort study.

Lisa M Prach, Lisa Pascopella, Pennan M Barry, Jennifer Flood, Travis C Porco, Philip C Hopewell, John Z Metcalfe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Are all antibiotic persisters created equal?Frontiers in cellular and infection microbiology · 2022
    Review
  4. Review
  5. Rifampin-resistant Tuberculosis in the United States, 1998-2014.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lisa M PrachaCenter for AIDS Prevention Studies (CAPS), University of California, San Francisco bTuberculosis Control Branch, Division of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, Richmond cF.I. Proctor Foundation, University of California, San Francisco dCurry International Tuberculosis Center, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA.
Lisa Pascopella
Pennan M Barry
Jennifer Flood
Travis C Porco
Philip C Hopewell
John Z Metcalfe

Funding

Effect of Drug Resistance on Transmissibility and Pathogenicity of M. tuberculosiR01AI076476 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPEWELL, PHILIP C · 2009 to 2013
$3.6M
Improving Early Identification of Drug Resistant Tuberculosis in HIV Prevalent SeK23AI094251 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI METCALFE, JOHN ZAPATA · 2011 to 2015
$625k
Framework to Address Drug Resistant Infections and Global HealthR24TW008822 · FIC · UNIVERSITY OF CALIFORNIA BERKELEY · PI RILEY, LEE W · 2010 to 2010
$425k
FIC NIH HHS R24 TW008822FIC NIH HHS R24TW008822NIAID NIH HHS K23 AI094251NIAID NIH HHS R01 AI076476
6 · The paper itself

Abstract

objectiveRifampin monoresistant tuberculosis (RMR-TB) is increasingly identified because of scale-up of rapid molecular tests. The longitudinal association of RMR-TB, multidrug-resistant TB (MDR-TB), and HIV/AIDS is incompletely described.

methodsWe examined clinical characteristics and treatment outcomes of patients with RMR-TB, isoniazid monoresistant TB (IMR-TB), MDR-TB, and drug-susceptible TB during a 16-year period (1993-2008) in California. TB cases were cross-matched with the state HIV/AIDS registry, and HIV prevalence denominators modeled using nonparametric backcalculation.

resultsOf 42,582 TB cases, 178 (0.4%), 3469 (8.1%), and 635 (1.5%) were RMR-TB, IMR-TB, and MDR-TB, respectively. From the pre-HAART (1993-1996) to HAART (2005-2008) era, RMR-TB rates declined rapidly (12.0 vs. 0.5 per 100,000) among patients with HIV infection. The proportion of patients for whom rifampin resistance indicated RMR-TB (rather than MDR-TB) decreased from 31% [95% confidence interval (CI) 26-38%] to 11% (95% CI 5-19%). In multivariate analysis controlling for HIV coinfection and other covariates, patients with RMR-TB were twice as likely to die as patients with drug-sensitive TB (relative risk 1.94, 95% CI 1.40-2.69).

conclusionRMR-TB/HIV rates declined substantially over time in association with improved TB control and HIV control in California. Mortality among patients with RMR-TB was high, even after adjusting for HIV status.

Indexed as

Drug Resistance, BacterialAdultAgedAntitubercular AgentsCaliforniaCohort StudiesComorbidityFemaleHIV InfectionsHumansIncidenceIsoniazidMaleMiddle AgedMycobacterium tuberculosisPrevalenceAntitubercular AgentsIsoniazidRifampin

Identifiers

PMID23842135
PMCPMC4296030

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.